My watch list  

Amal Therapeutics SA is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Amal was incorporated on September 3rd 2012 and secured seed funding in February 2014 to establish and validate its technology platform. Boehringer Ingelheim Venture Fund led this initial financing round, with the High-Tech Gründerfond. Over the past years, Amal Therapeutics has earned the recognition of several institutions and won several prizes or grants from different national and international funds including the Swiss commission for Technology and Innovation (CTI), the Eurostars programme, the Volkswirtschaftstiftung Swiss Foundation or the Fondation pour l’Innovation Technologique.


High-Tech Gründerfonds

More about Amal Therapeutics
  • News

    Boehringer Ingelheim acquires swiss biotech start-up

    Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first in class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is cur ... more

    AMAL Therapeutics closes series B financing round

    AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). The Company will use the funds to progress its lead vaccine ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE